
Medulloblastoma is a malignant tumour of the central nervous system (CNS). It develops in the cerebellum, which is located near the back of the brain.
Children and teenagers under the age of sixteen are primarily affected by medulloblastoma. It can happen to adults. However, it is less common in older people. Adults diagnosed with medulloblastoma often range in age from 20 to 45.
About 437 children and adults in the United States are affected by this uncommon form of cancer yearly. However, it is the most prevalent type of childhood brain tumour. Most cases are diagnosed between the ages of five and nine.
Early therapy is essential for medulloblastoma to improve survival rates, reduce tumour spread, and maintain brain function. Early management decreases recurrence risk and improves responses to chemotherapy, radiotherapy, and surgery. In addition to enhancing long-term results and quality of life for patients, early therapy also reduces the likelihood of cognitive and developmental deficits, especially in children. Treatment delays raise the possibility of metastases, brain damage, and decreased therapeutic efficacy.
Your age, the size of the tumour, and its stage of development are some variables that can affect the symptoms of medulloblastoma. These symptoms could be caused by a pressure buildup inside your head or the tumour's location. Some warning signs are:
Causes
The underlying cause of medulloblastoma is not entirely known, but it is thought to include mutations in the most essential pathways, such as TP53, SHH, and WNT. Hereditary genetic syndromes, including Li-Fraumeni syndrome, neurofibromatosis type 1, and Gorlin syndrome, predispose individuals. Environmental influences, especially radiation exposure, might also contribute. Medulloblastoma occurs more frequently in young children, particularly in males, but in most cases, there is no known cause.
Risk Factors
Risk factors for medulloblastoma are:
Recent research in the United Arab Emirates has significantly progressed in medulloblastoma treatment, particularly in the molecular classification of tumours. For better patient outcomes, research from leading institutions emphasises the importance of customised treatment regimes, such as the timing of delivering postoperative radiation. The UAE's commitment to embracing the latest scientific findings in applying clinical practice towards better prognosis and management is evident in these breakthroughs.
Surgery: If feasible, surgical tumour removal is often the initial step. The goal is to remove as much of the tumour as safely as possible to decrease the likelihood of recurrence.
Radiation Therapy: Following surgery, radiation treatment is frequently employed in an attempt to kill any residual tumour cells. Young children have specific methods used to reduce the effect on immature brain tissue since radiation has long-term side effects.
Gamma Knife Radio Surgery: A non-surgical treatment for medulloblastoma, Gamma Knife radiosurgery is employed to treat residual cancer cells following surgery or for inoperable tumours.
Cost Start From USD 6828 - USD 13657Explore Options
Cyberknife treatment: CyberKnife is an outpatient medulloblastoma treatment that accurately delivers focused radiation to tumours without surgery. It is ideal for tumours that are inoperable or in difficult-to-reach locations.
Cost Start From USD 5000 - USD 10000Explore Options
Chemotherapy: agents eliminate residual cancer cells and lower the threat of metastasis. It is administered before and after surgery or as part of treatment in the high-risk population.
Cost Start From USD 800 - USD 6000Explore Options
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services to support patients through Teleconsultations and online therapy sessions.









Sharjah, United Arab Emirates
Zulekha Hospital Sharjah located in Sharjah, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:

Abu Dhabi, United Arab Emirates
The Hospital owns an International Patient Services Team that is responsible to assist international patients with world-class healthcare, transportation arrangement, accommodation facilities, language interpreters, and much more.
Burjeel Medical City (about 1.2 million square facilities)provides 7-star hospitality to its patients. It has the largest facility space bed among all the private hospitals. The Hospital consists of-

Dubai, United Arab Emirates
Zulekha Hospital Dubai located in Dubai, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
The United Arab Emirates is growing in popularity as a place to treat medulloblastoma because of numerous essential benefits:
Radiation therapy is a crucial treatment for medulloblastoma; it is usually given following surgery to target any cancer cells that may still be present and lower the chance of recurrence. Craniospinal irradiation (CSI) is frequently used to treat the brain and spinal cord since the tumour can spread through the cerebrospinal fluid.
Radiation is essential for high-risk patients, but its use needs to be carefully controlled, especially in young children under three, to prevent long-term neurological problems. Although current methods try to minimise adverse effects, radiation increases survival rates and lowers the chance of relapse when used in conjunction with surgery and chemotherapy.
Medulloblastoma is often treated with chemotherapy, especially in high-risk pediatric cases. Chemotherapy is typically given after surgery and radiation therapy to target any remaining cancer cells and reduce the likelihood of recurrence. This approach is particularly important for enhancing the effectiveness of other treatments or for children who are too young to receive radiation. The combination of radiation, surgery, and chemotherapy improves overall survival rates and decreases the risk of relapse.
Factors such as age, tumour characteristics, and treatment response significantly determine the prognosis for medulloblastoma. Patients classified as high-risk tend to have a lower 5-year survival rate than those considered standard-risk, who typically have a survival rate of around 70–80%. While advancements in surgery, radiation, and chemotherapy have led to improved outcomes, challenges like relapse and long-term side effects remain prevalent. Early diagnosis and individualised treatment plans are crucial for enhancing survival rates.
While medulloblastoma typically spreads within the central nervous system, it can also extend to other body areas. The cerebrospinal fluid (CSF) can move to various parts of the brain and spinal cord. Although less common, it can sometimes reach distant sites such as the lungs or bones. Early detection and treatment are essential to prevent this spread and improve outcomes.
A medulloblastoma tumour's molecular subgroup (WNT, SHH, Group 3, or Group 4) is based on its genetic makeup and influences therapy options. Although Group 3 needs more aggressive therapy, other subgroups, like WNT-driven tumours, are more favourable and may require less aggressive treatment. Genetic testing helps tailor therapy for better outcomes and fewer side effects.
The side effects of medulloblastoma treatment include fatigue, loss of mental function, hair loss, and coordination problems. Although radiation can affect growth and brain function, especially in very young children, surgery can lead to neurological issues. Hair loss, nausea, and a weakened immune system are all potential side effects of chemotherapy. Long-term effects include hearing loss, endocrine problems, and learning difficulties. While improvements in therapy diminish these adverse effects, they can still affect the quality of the patient's life.
In the United Arab Emirates, children with medulloblastoma may truly recover with early detection and cutting-edge therapies like chemotherapy, radiation, and surgery. The UAE healthcare institutions offer the newest technologies and specialised pediatric treatment for the best possible recovery. With the proper care and monitoring, many kids see long-term improvements.
Medulloblastoma targets brain areas that control memory, learning, and movement, so that it can affect neurological and intellectual function. Chemotherapy, radiation, and surgery can affect memory, concentration, and coordination. Tumour location and treatment can result in long-term cognitive impairment and delays in development, particularly in children.
Recovery from medulloblastoma treatment in the UAE depends on the nature of the treatment and the patient's overall health and takes several months. The primary healing process after surgery can take 4–6 weeks, and the duration of chemotherapy and radiation could extend the healing process. Frequent follow-ups and rehabilitation are required to monitor improvement and regulate side effects for optimal outcomes.
Yes, you can get a second opinion on Medulloblastoma treatment in the United Arab Emirates through MediGence. With MediGence, you can connect with highly experienced professionals from top UAE hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from the United Arab Emirates's best hospitals. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.